Grant of options

RNS Number : 3031Q
Circassia Pharmaceuticals Plc
17 October 2019
 

Grant of options

Oxford, UK - 17 October 2019: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, announces that it has granted options ("Options") today over 1,630,435 new ordinary shares of 0.08 pence each in the Company ("Ordinary Shares") (representing 0.43% per cent. of the Company's issued share capital) to Jonathan Emms, who was appointed as Chief Operating Officer of the Company on 2 September 2019, under the 2019 Performance Share Plan.

The Options have been granted at a price of 0.08 pence per Ordinary Share, will vest on the third anniversary of the date of grant and are exercisable until the tenth anniversary of the date of grant. Vesting is subject to share price and sales performance conditions.

 

Contacts

 

Circassia

Steve Harris, Chief Executive Officer

Julien Cotta, Chief Financial Officer

Rob Budge, Corporate Communications

 

Tel: +44 (0)1865 405560

 

Peel Hunt (Nominated Adviser and Joint Broker)

James Steel / Dr Christopher Golden

 

Tel: +44 (0) 20 7418 8900

 

finnCap (Joint Broker)

Geoff Nash / Alice Lane

Tel: +44 (0) 20 7220 0500

Numis Securities (Joint Broker)

James Black / Freddie Barnfield

 

Tel: +44 (0) 20 7260 1000

 

FTI Consulting

Simon Conway / Ciara Martin

Tel: +44 (0) 20 3727 1000

 

 

 

 

 

 

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1.           

Details of the person discharging managerial responsibilities / person closely associated

a.            

Name

Jonathan Emms

2.            

Reason for the notification

a.            

Position/status

Chief Operating Officer

b.            

Initial notification

/Amendment

 

Initial notification

3.            

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.           

Name

Circassia Pharmaceuticals plc

b.           

LEI

2138006YAT138TOGA556

4.            

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.            

Description of the

Financial instrument, type of instrument

Identification code

Options over Ordinary shares of 0.08p each.

 

 

GB00BJVD3B28

b.            

Nature of the transaction

Award of share options granted under the 2019 Performance Share Plan over Ordinary Shares in Circassia

 

c.            

Price(s) and volume(s)

Price(s)

 

Volume(s)

£0.0008

1,630,435

      

d.            

Aggregated information

·    Aggregated volume

·    Price

 

 

 

n/a

 

e.            

Date of the transaction

2019-10-17

f.            

Place of the transaction

Outside a trading venue

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHBLBDGXXBBGCR

Companies

Niox Group (NIOX)
UK 100

Latest directors dealings